Aktuellt
SENASTE
Redeye comments on LIDDS Q2’22 report. The company advances its projects, in particular with regard to nanodotax and nanoimod. The collaboration with Johnson & Johnson has moved into the next phase and LIDDS’ leading project Liproca Depot is currently being prepared for a clinical Phase III trial. We will return with a research update, where we will review our financial forecasts and fair value range.
LÄS MER
